Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...
Compass Point is adopting a bullish stance on Nebius Group . The firm initiated the artificial intelligence infrastructure stock with a buy rating and price target of $150, implying upside of 54%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results